Reimbursement

While I'm far from being an expert in oncology, I strongly feel that anticancer treatments should be affordable.

Recent changes to reimbursement algorithms create new opportunities for consultant pharmacists to strengthen their contributions to managed care contracts.

Brian Cross, PharmD, BCACP, CDE, talks about why reimbursement seems to lag behind other changes in health care.

Bob Davis, PharmD, FAPhA, a professor of the Kennedy Pharmacy Innovation Center, talks about the center's Chronic Care Management program and opportunities for pharmacists to obtain reimbursement.

With prescription drug prices rising above reimbursement rates, many pharmacists are seeing patients struggle to access generic drugs.

Revenue stream bridges benefit community pharmacy in the transition to quality-based reimbursement.

Lindsey Crane, University of Oklahoma pharmacy student, discusses reimbursements and provider status for pharmacists.

Bipartisan legislation recently introduced, and endorsed today by the National Community Pharmacists Association , would help prevent community pharmacists from being collateral damage as some generic drug prices spike dramatically but federal health plan reimbursements fail to keep pace.

Hae Mi Choe, PharmD, describes how pharmacists can use metrics for reimbursement recognition.

Binita Patel, PharmD, MS, discusses how provider status would affect reimbursement models in ambulatory pharmacy.

The health of the profession of pharamacy depends upon pharmacists being fairly reimbursed for products and services provided.

As payers and providers are required to provide real-world outcomes data, there is high demand for the detailed financial reporting that an automated financial accruals process can produce. Here's what stakeholders need to know about the process.

Michael Einodshofer of Walgreens identifies the various charges that can be included in the total cost of an infusion in a hospital setting.

Einodshofer of Walgreens explains that it can be difficult to convince oncologists with hospital-owned oncology practices to send patients to alternative treatment sites.

A recent webinar from Zitter Health Insights highlighted the role of hubs and how these patient assistance programs are viewed by various stakeholders in the health care space.

Specialty tiers place an unfair burden on the most vulnerable patients, according to a new white paper from Medicare Access for Patients Rx.

Experience with biologics and biosimilar products means a high level of trust from US payers, according to a report from BioTrends Research Group.

Many factors come into play when establishing a distribution model, and the 3 P's-Pharmacy, Payer, and Product-are all key stakeholders and part of the story.

Michael Einodshofer, director, utilization management, Walgreens, describes how contractual methodologies and cost differences across various sites of service can influence how a specialty drug is reimbursed under the medical benefit.

Results from a recent survey indicate that although payers are more familiar with specialty drugs, nearly half are not satisfied with their specialty pharmacy provider's adherence measurements.

We sat down with Kjel A. Johnson, PharmD, senior vice president, Strategy & Business Development, Magellan Pharmacy Solutions, to learn more about buy-and-bill practices, 340b drug pricing, and how site-of-care changes may affect the drugs covered under the medical benefit.

To provide complete services to the specialty patient in the home care setting, specialty pharmacies and specialty nurses need to clearly define their individual responsibilities.

The central intake model allows specialty pharmacies to manage patient information from multiple sources more efficiently. The potential benefits of centralized information and administration include better therapy management and increased customer loyalty.

Copay organizations play an important role in helping patients obtain their medications and have become integral partner with specialty pharmacies as they work together to support different therapies.

Orphan drug development has taken off as this segment of the industry has seen impressive growth. Here's an expert analysis of the orphan market by an industry leader outlining the challenges and opportunities.

Complaints about PBM reimbursement are industry-wide. What can be done?

NACDS and the California Retailers Association voice support for cost-saving alternatives that would still enable patient access to pharmacists.

Budget cuts in New York are leading to pharmacy closures.